Pipeline

New products under development

Auxesis Pharma develops next-generation topical treatments based on research in dermatology, pain control and formulation technology. Loperaderm and Cutivelle are working names for formulations intended to provide pain blocking for more severe wound care as well as removal of certain skin spots. Information about future medicines is published continuously on the website.

Opioid

LOPERADERM™ — (Working name)

Opioid is a synthetic opioid anti-diarrheal that acts locally in the gut. Research has shown that topical opioids can provide localized pain-control effect …

  • Non-addictive
  • Does not cross the blood-brain barrier
  • Metabolized in the liver
  • Prescription-only
Under development
LOPERADERM™ — (Working name)

About LOPERADERM™ — (Working name)

Opioid receptors also exist in peripheral nerves and skin cells, which means topically applied loperamide may provide localized pain-control without significant systemic effects.

Research suggests opioid receptors may influence wound healing and cell migration.

Keratosis

Cutivelle™ — (Working name)

Keratoses are very common and benign skin changes, most often appearing from middle age and up and varying in color and shape …

  • Most common benign skin tumor
  • Non-invasive treatment
  • Cosmetic improvement
  • OTC
Under development
Cutivelle™ — (Working name)

About Cutivelle™ — (Working name)

Seborrheic keratosis arises through proliferation of keratinocytes in the epidermis and is strongly age-related with genetic predisposition.

Treatment is usually not medically necessary but may be performed for functional or cosmetic reasons.